🟢 20/20 Biolabs is trading 6.94% up today after Q2 revenue rose 36.5%

20/20 Biolabs is trading at $0.55, up 6.94% on August 21, 2026, following Q2 revenue growth and gross-margin expansion.

• Q2 revenue rose 36.5% to $0.7 million, while gross margin expanded to 41.7%.
• OneTest revenue increased 47.1%, and gross profit rose 86.6%, supporting renewed investor interest despite a wider quarterly loss and $0.26 loss per share.
• Biotech sector strength is providing additional support.